Really enjoyed this write up! Curious at the end you mentioned other opportunities are potentially more attractive. What tools in particular are you more interested in - or just companies like AVTR? Any views on DHR?
At the time of this writing I was also watching the clinical CROs IQV and ICLR. Both had traded off heavily with so much less of the risk to their numbers. I think the funding data now suggests it's time to put more exposure to the macro on, however, and Catalent is still the one of the cheapest things you can own if you believe they'll put up good cost control in FY24
Really enjoyed this write up! Curious at the end you mentioned other opportunities are potentially more attractive. What tools in particular are you more interested in - or just companies like AVTR? Any views on DHR?
At the time of this writing I was also watching the clinical CROs IQV and ICLR. Both had traded off heavily with so much less of the risk to their numbers. I think the funding data now suggests it's time to put more exposure to the macro on, however, and Catalent is still the one of the cheapest things you can own if you believe they'll put up good cost control in FY24